erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the..

loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people... march 2017  (21)..
the software identified and measured a marker of svd and then gave a score indicating how severe the disease was ranging from mild to severe.